Evidence Hub

Vitamin D Supplementation Dose as The Prevention of Fragility Fracture In Chronic Kidney Disease Patient: A Systematic Review

Aldico J Sapardan, R. S. Djatnika

Jurnal Sehat Indonesia (JUSINDO), 2024

Abstract

CKD affects more than 10% of the global population. It can cause osteoporosis and increase the risk of fractures, especially as CKD becomes more serious. In CKD, mineral and bone disorders (CKD-MBD) cause abnormalities in how the body processes vitamin D, calcium, phosphorus, or parathyroid hormone (PTH). It can also affect bone strength and cause calcium build-up in the soft tissues. Treatment usually starts with correcting the chemical abnormalities that occur in the body due to CKD-MBD before focusing on osteoporosis and fractures. A study review spanning 2010 to 2023 investigated optimal vitamin D supplementation doses in CKD patients, indicating varied outcomes influenced by factors like dosage, duration, and population characteristics. Doses ranged from 800 to 8,000 IU/day of cholecalciferol, with recommendations contingent on serum 25(OH)D levels.

How strong is the evidence?

Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free